BAM
VNDA icon

Blueshift Asset Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Blueshift Asset Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-14,574
Closed -$205K – 975
2019
Q2 		$205K Buy
+14,574
New +$232K 0.03% 649

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Blueshift Asset Management's VNDA Position: Q3 2019 in Review

Blueshift Asset Management sold out of Vanda Pharmaceuticals (VNDA) in Q3 2019, closing a stake of 14,574 shares — an estimated $205K sold.

Blueshift Asset Management first reported a position in VNDA in Q2 2019 and held it in 1 quarter. The position peaked at $205K in Q2 2019. 168 funds tracked by Wall St. Rank hold VNDA as of Q3 2019.

  • Blueshift Asset Management reported no remaining Vanda Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Blueshift Asset Management sold 14,574 Vanda Pharmaceuticals shares in Q3 2019, an estimated $205K.
  • Blueshift Asset Management first reported a position in Vanda Pharmaceuticals in Q2 2019 and held it in 1 quarter.
  • Blueshift Asset Management's Vanda Pharmaceuticals position peaked at $205K in Q2 2019.
  • 168 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2019.

Based on Blueshift Asset Management's 13F filing for Q3 2019, filed 12 Nov 2019.